Trading on a split-adjusted basis will begin at market open on November 11, 2026. This adjustment is expected to help Silexion regain compliance with the Nasdaq minimum bid price requirement, enhance its market position, and support its clinical progress with SIL204 Grand Cayman, Cayman Islands, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-dr
Tipranks Press Release.
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 11.0% to $0.17 during Friday's after-market session. The company's market cap stands at $2.4 million. Lexaria Bioscience (NASDAQ:LEXX) stock
Silexion Therapeutics has moved SIL204 into active patient treatment, beginning a multinational Phase 2/3 study that will evaluate the RNAi candidate alongside standard chemotherapy in locally advanced pancreatic cancer. Key Investor TakeawaysSilexion Therapeutics (NASDAQ:SLXN) has successfully dosed the first patient in its Phase 2/3 SIL204 trial, moving the programme into active clinical execution.
Detailed price information for Silexion Therapeutics Corp (SLXN-Q) from The Globe and Mail including charting and trades.
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 26.8% to $0.32 during Tuesday's pre-market session. The company's market cap stands at $1.3 million. Summit Therapeutics (NASDAQ:SMMT) stock rose 16.34%
Cayman Islands, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding series E warrants to purchase up to an aggregate of 3,216,928 of the Company’s ordinary shares originally issued in August 2026 having a reduced exercise price of
Silexion Therapeutics shares jump after hours on positive SIL204 preclinical findings for KRAS-driven cancers.
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 27.1% to $0.31 during Monday's after-market session. The market value of their outstanding shares is at $1.4 million. Chemomab Therapeutics (NASDAQ:CMMB)
Tipranks Press Release.
Detailed price information for Silexion Therapeutics Corp (SLXN-Q) from The Globe and Mail including charting and trades.
Find the latest Silexion Therapeutics Corp (SLXNW) stock quote, history, news and other vital information to help you with your stock trading and investing.
Grand Cayman, Cayman Islands, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that members of its management team will participate in the following industry and investor conferences in September 2026: Oncology & Immunology Innovation Partnering & Licensing SummitPresentation date: September 9, 2026Location: Hotel
Detailed price information for Silexion Therapeutics Corp (SLXN-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.